Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone for Hepatic Fibrosis in Chronic Hepatitis B
NCT07412236Phase 3Not yet recruiting
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydronidone in Liver Fibrosis (LF), sponsored by Gyre Pharmaceuticals. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07412236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412236.